ANG Lifesciences Share Price | ANG Lifesciences Stock Screener
ANG
Pharmaceuticals
Share Price BSE
₹34.36
▼
-0.58 (-1.66%)
As of July 3, 2026, the ANG Lifesciences share price (BSE: ANG) is ₹34.36, down 1.66% from the previous close, with shares trading between ₹33.20 and ₹35.65, and a 52-week range of ₹18.42–₹42.83.
Analyse ANG stock price history and track historical price performance.
Use the ANG Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
ANG Lifesciences Market Cap
₹50.45 Cr.
ANG P/E Ratio (TTM)
-4.79
ANG Lifesciences P/B Ratio
1.00
EPS (TTM)
₹-8.43
Dividend Yield
-
Debt to Equity
1.11
ANG 52 Week High
₹42.83
ANG Lifesciences 52 Week Low
₹18.42
Operating Margin
11.00%
Profit Margin
-4.17%
ANG Revenue (TTM)
₹24.00
EBITDA
₹3.00
Net Income
₹-1.00
Total Assets
₹209.00
Total Equity
₹53.00
ANG Lifesciences Share Price Chart
Screen ANG Lifesciences share price with an interactive chart. Analyse ANG price trends and volatility across different timeframes.
ANG Lifesciences Company Profile - Fundamental Screener
Screen ANG Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ANG shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE236W01016
ANG Lifesciences Balance Sheet Screener
Screen ANG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 209 | 230 | 242 | 278 | 291 |
| Current Assets | 145 | 161 | 173 | 183 | 193 |
| Fixed Assets | 51 | 57 | 58 | 88 | 93 |
| Liabilities | |||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 7 | 22 | 22 | 29 | 41 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 53 | 64 | 76 | 86 | 84 |
| Share Capital | 13 | 13 | 13 | 13 | 10 |
| Reserves & Surplus | 40 | 46 | 59 | 69 | 69 |
ANG Lifesciences Income Statement Screener - Profit & Revenue Analysis
Screen ANG Lifesciences income statement and profit fundamentals.
Analyze ANG quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for ANG Lifesciences share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24 | 19 | 26 | 25 | 18 | 25 | 33 | 20 | 38 | 19 | 34 | 57 | 49 | 47 | 60 |
| Expenses | 21 | 21 | 26 | 24 | 18 | 27 | 31 | 20 | 36 | 21 | 32 | 50 | 50 | 44 | 50 |
| EBITDA | 3 | -3 | 0 | 1 | 0 | -2 | 3 | 0 | 2 | -2 | 2 | 7 | -1 | 3 | 10 |
| Operating Profit % | 11.00% | -14.00% | 0.00% | 3.00% | -4.00% | -9.00% | 7.00% | -9.00% | 4.00% | -10.00% | 5.00% | 12.00% | -26.00% | 6.00% | 16.00% |
| Depreciation | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 2 | 2 | 2 | 4 | 3 |
| Profit Before Tax | -1 | -6 | -3 | -3 | -4 | -6 | -1 | -4 | -4 | -6 | -3 | 2 | -6 | -3 | 4 |
| Tax | 0 | -1 | 0 | -1 | -2 | -1 | 1 | -1 | 0 | 0 | 0 | 1 | -1 | -1 | 2 |
| Net Profit | -1 | -5 | -3 | -2 | -2 | -5 | -2 | -3 | -4 | -6 | -2 | 2 | -5 | -2 | 3 |
| EPS | -1.07 | -3.60 | -2.24 | -1.52 | -1.56 | -3.98 | -1.53 | -2.35 | -2.75 | -4.52 | -1.74 | 1.41 | -3.63 | -1.36 | 2.20 |
ANG Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen ANG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|
| Operating Activities | 0 | -10 | 26 | 25 |
| Investing Activities | -2 | 20 | -9 | -44 |
| Financing Activities | 2 | -10 | -17 | 20 |
| Net Cash Flow | 0 | 0 | 0 | 0 |
ANG Lifesciences Shareholding Pattern Screener
See ANG Lifesciences shareholding pattern with promoter, FII, and DII holdings.
Check ANG Lifesciences promoter holding and ownership changes for ANG on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 26.21% | 26.26% | 26.18% | 26.11% | 26.11% | 25.92% | 25.45% | 25.48% |
| Other Holding | 3.19% | 3.13% | 3.21% | 3.29% | 3.29% | 3.48% | 3.95% | 3.92% |
| Shareholder Count | 5,952 | 6,084 | 6,273 | 6,400 | 6,508 | 6,517 | 6,468 | 6,631 |
ANG Lifesciences Share Dividend Screener - Share Yield Analysis
Check ANG Lifesciences dividend history with payout and yield data.
View ANG Lifesciences dividend details including ex-dates and amounts for ANG stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹1.00 | 1.33% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
ANG Lifesciences Stock Index Membership
See which indices include ANG Lifesciences stock.
Check ANG index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
ANG Lifesciences Market Events Screener - Corporate Actions
Get ANG Lifesciences corporate actions including splits, bonuses, and buybacks.
Check ANG Lifesciences stock events that may affect ANG share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -8.62% | ||
| Bonus | 1:1 | - | ||
| Annual General Meeting | NA | -1.68% | ||
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | -5.73% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | 3.50% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -2.04% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -3.93% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -5.27% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -5.83% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -4.04% |
| 2022-07-13 | 2022-07-14 | Bonus | 1:4 | 36.04% |
| 2021-11-02 | 2021-11-04 | Dividend | ₹ 1.00 /share | 47.69% |
ANG Lifesciences Competitors Screener - Peer Comparison
Screen ANG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 446,876 | 39.04 | 58,220 | 6.38% | 11,565 | 60.32 |
| Divis Laboratories | 174,652 | 67.84 | 10,560 | 8.73% | 2,520 | 44.73 |
| Torrent Pharmaceuticals | 156,365 | 73.76 | 13,886 | 20.34% | 2,138 | 62.27 |
| Cipla | 118,382 | 30.41 | 29,045 | 2.24% | 3,870 | 69.96 |
| Dr Reddys Laboratories | 113,273 | 27.63 | 33,593 | -0.44% | 3,998 | 66.21 |
| Zydus Life Science | 111,954 | 22.03 | 26,720 | 13.65% | 5,242 | 62.64 |
| Lupin | 110,605 | 20.55 | 27,488 | 19.98% | 5,345 | 68.05 |
| Mankind Pharma | 105,132 | 52.96 | 14,278 | 12.03% | 1,750 | 64.79 |
| Aurobindo Pharma | 90,835 | 25.68 | 33,385 | 3.21% | 3,376 | 69.05 |
| Laurus Labs | 81,918 | 91.20 | 6,868 | 22.01% | 890 | 72.35 |
ANG Lifesciences Company Announcements - News Screener
Screen ANG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-06-19 | Closure of Trading Window | - |
| 2026-06-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-30 | Results - 31.03.2026 | - |
| 2026-05-30 | Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended 31St March 2026 | - |
| 2026-05-29 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-22 | Board Meeting Intimation for Considering The Standalone & Consolidated Audited Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-04-17 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-10 | Clarification On Price Movement In Shares | - |
| 2026-04-10 | Clarification sought from ANG Lifesciences India Ltd | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-02-14 | Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025 | - |
| 2026-02-14 | Board Meeting Outcome for Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025 | - |
| 2026-02-06 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-02-05 | Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended And Nine Months Ended On 31St December 2025. | - |
| 2026-01-22 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-22 | Closure of Trading Window | - |
| 2025-11-14 | Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2025 | - |
| 2025-11-14 | Board Meeting Outcome for Board Meeting Outcome For To Consider And Approve The Financial Results For The Quarter And Half Year Ended 30-09-2025 | - |
| 2025-11-06 | Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended On 30Th September 2025. | - |